Quick AI research

based on a quick AI research:

AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.

Based on the recent clinical data, here are Cogent Biosciences' potential advantages:

1. Efficacy Advantages:

   ◦ 83% ORR (mIWG criteria)

   ◦ 100% ORR (PPR criteria)

– Higher response rate at optimal dose (100mg BID):

– Quick response time (2.2 months)

– Potentially better than existing treatments

1. Potential Market Differentiation:

– May have better safety profile

– Could be more selective/targeted

– Potential for different dosing regimen

– Might work in resistant cases

1. Later Market Entry Benefits:

– Learn from competitors' experience

– Better understanding of patient needs

– Improved trial design

– Known market dynamics

To market timeline:

Best Case Scenario:

   ◦ Phase 2 data sufficient

   ◦ Gets accelerated approval

   ◦ Priority review granted

– Could be approved in 1-2 years if:

Conservative Estimate:

   ◦ Phase 3 required

   ◦ Standard review process

   ◦ No major delays

– 2-3 years if:

– Phase 3 required

– Standard review process

– No major delays

Remember: These are estimates based on typical timelines; actual timing could vary significantly based on multiple factors.